natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the patient experiences an improvement in blood oxygen saturation for at least 15 days after the administration period ends, as compared to the blood oxygen saturation of the patient prior to the administration period. 
Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-12, naznačen time, što kod pacijenta dolazi do poboljšanja zasićenosti krvi kisikom tokom najmanje 15 dana nakon završetka perioda primijene, u usporedbi sa zasićenošću krvi kisikom kod pacijenta prije perioda primijene.
withdrawing at least part of said mixture from an agitated chamber by means of a circulation pump, and 
povlačenje najmanje dijela navedene smjese iz komore za miješanje pomoću cirkulacijske pumpe (2), te
A pharmaceutical product characterized in that it consists of B2-microglobulin or of a functional variant of that protein presenting at least 70% identity with the human B2-microglobulin protein, as active ingredient, in a pharmaceutically acceptable carrier, for use in the treatment of an autoimmune disease. 
Farmaceutski proizvod karakteriziran na način da se sastoji od B2-mikroglobulina ili funkcionalne varijante tog proteina koji pokazuje najmanje 70% identičnosti s ljudskim proteinom B2-mikroglobulinom, kao aktivnim sastojkom, u farmaceutski prihvatljivom nosaču, za uporabu u liječenju autoimune bolesti.
Developer supply container and developer supplying system 
SPREMNIK ZA NADOPUNJAVANJE RAZVIJAČA I SUSTAV ZA NADOPUNJAVANJE RAZVIJAČA
B is selected from -O-R', -NHR", -SR'" or-OH; and R', R" and R"' are independently different or identical and is selected from one or the formulas below: 
Q B je odabran od -O-R', -NHR", -SR'" ili-OH; 1 R', R"1R'" su neovisno različiti ili identični 1 odabrani su od jedne 1li više formula ispod:
the means for causing said material to pass through said irradiation volume comprises a vehicle for transporting said Flash X-ray source in such a way as to cause said irradiation volume to pass through in-situ material. 
Spojevi pomoću kojih navedeni materijal prolazi kroz ozračeno polje koje sadrži pokretni izvor treptajućih rengenskih zraka i to na način da omogućuje da ozračeno polje prolazi kroz in-situ materijale.
The radio communication method according to claim 7, comprising: receiving higher layer control information indicating control of the transmission power value of the A-SRS using the second accumulation value. 
Postupak radio komunikacije sukladno zahtjevu 5, sadržeći primanje kontrolne informacije višeg sloja, naznačeno time da se navedeno upravljanje vrijednosti snage prijenosa A-SRS-a inicira nakon navedenog primanja kontrolne informacije višeg sloja.
In yet another embodiment of the dosage form, the dosage form comprises 45.5 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, 3.5 mg of hypromellose, 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, and 1.9 mg of talc extra fine. In yet another embodiment of the dosage form described herein, the dosage form further comprises 2.0 mg of a color coating agent. 
Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je jezgra u obliku tablete, kod čega je sadržaj rasagilina 0,5 mg, a tableta sadrži 45,5 mg manitola, 0,4 mg aerosila, 5,0 mg škroba NF, 20,0 mg prethodno želatiniranog škroba, 1,5 mg stearinske kiseline, 1,5 mg talka, 3,5 mg hipromeloze, 4,0 mg kopolimera metakrilna kiselina - etil akrilat, 0,8 mg trietil citrata, 1,9 mg ekstra finog talka i 2,0 mg agensa za boju obloge.
The floor of the suction chambers 48 communicates with a feeder screw 52 designed to remove the already ground waste. The operating principle of these embodiments of the mill 20 is explained hereinbelow. 
Mlin (20) sukladno zahtjevu 1, pri čemu pod usisnih komora (48) komunicira s opskrbnim vijkom (52) dizajniranim da otklanja samljeveni otpad.
a non-ionic emulsifier selected from the group consisting of cetearyl alcohol, ceteareth-12, ceteareth-20 and mixtures thereof, in the range from 0.5 to 15.0 % w/w; 
neionskog emulgatora izabranog iz grupe koja se sastoji od cetearil alkohola, cetearet-12, cetearet-20 i njihove smjese, u rasponu od 0,5 do 15,0 % wt/wt;
➢ R3a and R3b together with the carbon atom to which they are attached to form a carbonyl group, or ➢ two of R2a, R2b, R3a and R3b independently represent hydrogen, or (C1-3)alkyl; 
a i R3b zajedno s ugljikovim atomom na kojega su priključeni, tvore karbonil-skupinu, ili dva od R2a, R2b, R3a i R3b neovisno predstavljaju vodik, ili (C13)alkil;
In one embodiment, the air atomized aluminum powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between about 4 to 7 microns and the 90th percentile of the particle size distribution has a diameter of less than or equal to about 11.5-15.5 microns; this powder will be referred to further as Al powder “Type AA”. 
Gusta smjesa iz patentnog zahtjeva 1 ili 3, pri čemu aluminij ili prah aluminijeve slitine obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 4 i 7 mikrometara (mikrona) i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 11.5-15.5 mikrometara.
The composition of Claim 25, wherein a second therapeutic agent is present and is selected from anti-Alzheimer's agents, anticonvulsants, antidepressants, anti-Parkinson's agents, dual serotonin-norepinephrine reuptake inhibitors, non-steroidal anti-inflammatory agents, norepinephrine reuptake inhibitors, opioid agonists, opioid antagonists, selective serotonin reuptake inhibitors, sodium channel blockers, sympatholytics, and combinations thereof. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 25, naznačen time, da je nazočno drugo terapijsko sredstvo i da je odabrano od sredstava protiv Alzheimerove bolesti, antikonvulzanata, antidepresiva, sredstava protiv Parkinsonove bolesti, dvojnih serotonin-norepinefrinskih povratnih inhibitora, nesteroidnih protu-upalnih sredstava, norepinefrinskih povratnih inhibitora, opioidnih agonista, opioidnih antagonista, selektivnih serotonininskih povratnih inhibitora, blokatora natrijevih kanala, simpatolitika i njihovih kombinacija.
The compound or composition of any of claims 6-9, wherein the method comprises administering at least one therapeutic agent selected from an anti-inflammatory agent, an immunosuppressive agent, an anti-diabetic agent, digoxin, a vasodilator, an angiotensin II converting enzyme (ACE) inhibitors, an angiotensin II receptor blockers (ARB), a calcium channel blocker, an isosorbide dinitrate, a hydralazine, a nitrate, a hydralazine, a beta-blocker, a natriuretic peptides, a heparinoid, and a connective tissue growth factor inhibitor. 
Spoj ili pripravak prema bilo kojem od zahtjeva 6-9, naznačen time da postupak obuhvaća davanje barem jednog terapeutskog sredstva odabranog od protu-upalnog sredstva, imunosupresivnog sredstva, antidijabetičkog sredstva, digoksina, vazodilatatora, inhibitora angiotenzin II konvertirajućeg enzima (ACE), blokatora angiotenzinskih II receptora (ARB), blokatora kalcijevih kanala, izosorbid dinitrata, hidralazina, nitrata, hidralazina, beta-blokatora, natriuretskih peptida, heparinoida, te inhibitora faktora rasta vezivnog tkiva.
The compound according to claim 7 wherein R1, R2, R3 are hydrogen; 
Spoj u skladu s patentnim zahtjevom 5, naznačen time, da su R1, R2, R3 vodik;
The process of any preceding claim, wherein the vaccine is a trivalent influenza vaccine. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da cjepivo jest trovalentno cjepivo protiv gripe.
The compound of Formula LXXII can be further hydrolysed to form a compound of Formula XX. 
R-a j. = skidanje zaštite sa spoja Formule L, čime se dobiva spoj Formule LI:
Such GI motility disorders include, by way of illustration, chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), diabetic and idiopathic gastroparesis, and functional dyspepsia. In one aspect, therefore, the invention provides a method of increasing motility of the gastrointestinal tract in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a crystalline salt of the invention. When used to treat disorders of reduced motility of the GI tract or other conditions mediated by 5-HT4 receptors, the salt forms of the invention will typically be administered orally in a single daily dose or in multiple doses per day, although other forms of administration may be used. 
Spoj u obliku kristalne soli u skladu s patentnim zahtjevom 15, naznačen time, da je poremećaj smanjenog motiliteta odabran između sljedećeg: kronična konstipacija, sindrom nadraženog crijeva s predominantnom konstipacijom, dijabetička 1 idiopatska gastropareza i funkcionalna dispepsija. Uporaba spoja u obliku kristalne soli iz bilo kojeg od patentnih zahtjeva 1 do 12, naznačena time, da se ta uporaba odnosi na proizvodnju lijeka za liječenje medicinskog stanja u sisavaca, a to medicinsko stanje je poremećaj ili smanjeni motilitet gastrointestinalnog sustava, Uporaba u skladu s patentnim zahtjevom 17, naznačena time, da je dotično medicinsko stanje odabrano iz sljedećeg: kronična konstipacija, sindrom nadraženog crijeva s predominantnom konstipacijom, dijabetička i idiopatska gastropareza i funkcionalna dispepsija.
The use of claim 2, wherein: X is optionally substituted pyrazolene, Y is a covalent bond, C1-6 alkylene optionally substituted by hydroxy, alkoxy, optionally substituted amino, or -COR, in which R is hydroxy, alkoxy or amino; and 
X je opcijski supstituirani pirazolin, Y je kovalentna veza, C1-6alkilen opcijski supstituiran sa hidroksi, alkoksi, opcijski supstituirani amino, ili -COR, u kojem je R hidroksi, alkoksi ili amino; i Z je vodik, opcijski supstituirani fenil, opcijski supstituirani oksadiazolil, opcijski supstituirani izoksazolil, ili opcijski supstituirani piridil.
An immunogenic composition according to claim 1 or 2 wherein 19F capsular saccharide is conjugated to the carrier protein via a linker for use in the treatment or prevention of diseases caused by Streptococcus pneumoniae infection by serotype 19A strains. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1 ili 2, gdje je saharid iz kapsule sarotipa 19F konjugiran s proteinom-nosačem preko spojnice, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti uzrokovanih infekcijom sojevima serotipa 19A bakterije Streptococcus pneumoniae.
Metal charge solution: 0.2 M Copper Sulphate 
- < Otopina s nabijenim metalom: 0.2 M bakar sulfat
the first mobile station identity is C-RNTI, and the second mobile station identity is C-RNTI for periodic channel state reporting. A mobile communication system in which a mobile station apparatus searches a physical downlink control channel transmitted by a base station apparatus in a search space, the mobile communication system comprising: the base station apparatus which transmits to the mobile station apparatus, in the search space, a first physical downlink control channel including a first mobile station identity or a second physical downlink control channel including a second mobile station identity, the search space is defined based on the first mobile station identity, in a case that the mobile station apparatus has the first mobile station identity and the second mobile station identity, and 
Uređaj bazne stanice koji je prilagođen za odašiljanje, na uređaj mobilne stanice, kontrolnog kanala fizičke silazno veze, PDCCH, u prostoru pretraživanja, naznačen time da uređaj bazne stanice sadrži: sredstva podešena za odašiljanje na uređaj mobilne stanice, u prostoru pretraživanja, te PDCCH sadrži identitet prve mobilne stanice ili identitet druge mobilne stanice, pri čemu je prostor pretraživanja određen na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identitet druge mobilne stanice; PDCCH se koristi za dinamično raspoređivanje kada PDCCH sadrži identitet prve mobilne stanice; a PDCCH se koristi za aktiviranje trajnog raspoređivanja kada PDCCH sadrži identitet druge mobilne stanice.
The mooring system (1) in accordance with claim 1, characterized in that the round sling (6) includes an inner sheath (69) and an outer sheath (68). 
Sustav za privez (1) u skladu sa zahtjevom 1, naznačen time što okrugla omča (6) obuhvaća unutarnji plašt (69) 1 vanjski plašt (68).
a cap, where the cap has a ring shaped cross-section and is sized and shaped so as to be connectable to the base around the second end of the base such that the port is accessible when the cap is connected to the base. The device of claim 1, wherein: the base includes protrusions on the second side of the base; and 
Uređaj prema zahtjevu 1, naznačen time, da: baza obuhvaća izbočine na drugoj strani baze; i kapica je djelotvorno uređena da škljocajem zahvati izbočine, kako bi se kapica učvrstila za bazu.
The compound or pharmacologically acceptable salt thereof according to claim 1 or claim 2, wherein Ar2 is a phenyl group. 
Spoj ili njegova farmakološki prihvatljiva sol u skladu s patentnim zahtjevom 1 ili patentni zahtjev 2, naznačen time, da je Ar2 fenilna skupina.
A combination of oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain, wherein 80 mg up to 160 mg of oxycodone or a pharmaceutical acceptable salt thereof are administered orally per day together with naloxone or a pharmaceutically acceptable salt thereof, wherein the weight ratio of oxycodone:naloxone is 2:1, and wherein oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof are released in a sustained manner. The combination for use according to claim 1, wherein the pain is moderate to severe pain. 
Farmaceutski oblik doziranja s produljenim oslobađanjem koji sadrži 40 mg oksikodona ili njegove farmaceutski prihvatljive soli i 20 mg naloksona ili njegove farmaceutski prihvatljive soli, gdje su oksikodon ili njegova farmaceutski prihvatljiva sol i nalokson ili njegova farmaceutski prihvatljiva sol prisutni u težinskom omjeru od 2:1, za upotrebu u liječenju umjerene do jake boli i opioidom izazvanih sindroma crijevne disfunkcije koji se javljaju tijekom terapije protiv bolova, gdje je navedeni opioidom izazvani sindrom crijevne disfunkcije zatvor, i neželjenih efekata, gdje su navedeni neželjeni efekti tipični naloksonom izazvani neželjeni efekti odabrani iz skupine koja se sastoji od bolova u trbuhu, grčeva i dijareje.
As another aspect, the present invention provides the use of anhydrous crystalline orvepitant maleate (Form 1) according to the present invention in the preparation of a medicament for the treatment or prophylaxis of depression, anxiety, posttraumatic stress disorders, emesis and/or sleep disorders. 
Uporaba anhidriranog, kristalnog orvepitant-maleata (Oblik 1), prema bilo kojem od Zahtjeva 1-3, za dobijanje medikamenta za tretman ili profilaksu depresije, anksioznosti, poremećaja post-traumatskog stresa, povraćanja i/ili poremećaja spavanja.
A pharmaceutical composition according to claim 46 wherein the form is suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler, or a metered dose inhaler. 
Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se primjena provodi putem dozatora za medikament koji se bira između inhalatora sa spremnikom suhog praha, višedoznog inhalatora sa suhim prahom ili inhalatora za odmjerene doze.
The crystalline form C according to claim 1 having absorption bands at wavenumbers of 1324 ± 1 cm-1 and 579 ± 1 cm-1 in an infrared absorption spectrum measured according to the ATR method as described in the Japanese Pharmacopeia 14th Edition, General Tests by using FT-IR Spektrum-One with a measurement range of 4000 - 400 cm-1 and a resolution of 4 cm-1. 
Kristalni oblik C prema zahtjevu 1, naznačen time, da ima apsorpcijske pojaseve kod valnih brojeva od 1324 + 1 cm" i 579 + 1 cm" u infracrvenom apsorpcijskom spektru mjereno u skladu s ATR postupkom kako je opisano u 14. izdanju Japanske Farmakopeje, opći testovi uz uporabu uređaja FT-IR Spektrum-One s rasponom mjerenja od 4000 - 400 em"' i uz razlučivost od 4 cm".
R<28> is hydrogen, substituted or unsubstituted C1-C4 linear alkyl, substituted or unsubstituted C6 or C10 aryl, substituted or unsubstituted C1-C9 heterocyclic, substituted or unsubstituted C1-C11 heteroaryl; 
R'* je vodik, supstituirani ili nesupstituirani C,-C, nerazgranati alkil, C, ili C,, supstituirani ili nesupstituirani aril, Ci-Co supstituirani ili nesupstituirani heterocikl, C;-C;, supstituirani ili nesupstituirani heteroaril;
Exemplary compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. 
Primjeri sastava za oralni unos uključuju suspenzije koje mogu sadržavati, npr., mikrokristalnu celulozu za davanje volumena, alginske kiseline ili natrijev alginat kao sredstvo za stvaranje suspenzije, metilceluloza za povećanje viskoziteta i sredstva za zaslađivanje ili aromu kao što su oni poznati u struci; i tablete za izravno oslobađanje koje mogu sadržavati, npr., mikrokristalnu celulozu, dikalcijeve fosfate, škrob, magnezijev stearat i/ili laktozu i/ili druga pomoćna sredstva, vezivna sredstva, sredstva za produživanje, razgrađivanje, razrjeđivanje i podmazivanje kao što su ona poznata u struci.
This sensor (261) is located at least one air measurement station (262) located at a distance wherein it will not be affected by the spraying components (240). 
Rashladni sustav prema patentnom zahtjevu 1, naznačen time da, spomenuti senzor (261) sadrži najmanje jednu stanicu za mjerenje zraka (262) u kojoj je smješten spomenuti senzor (261).
The 8th item relates to a floor panel according to the 7th item, characterized in that it comprises a stop-forming part (26), which, in a distal direction in respect to the floor panel (1), forms a blockage for the support portion (20). 
Podni panel sukladno zahtjevu 7, naznačen time što sadrži dio za zaustavljanje formiranja (26), koji, u distalnom smjeru u odnosu na podni panel (1), formira blokadu za potporni dio (20).
at least one drug selected from the group consisting of a serotonin reuptake inhibitor and a serotonin and norepinephrine reuptake inhibitor; wherein said serotonin reuptake inhibitor is at least one drug selected from the group consisting of fluoxetine, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof, and said serotonin and norepinephrine reuptake inhibitor is at least one drug selected from the group consisting of venlafaxine, duloxetine, milnacipran, desvenlafaxine and salts thereof. 
(ID) najmanje jedan lijek odabran iz skupine koja se sastoji od inhibitora povratne apsorpcije serotonina, i inhibitora povratne apsorpcije serotonina i noradrenalina; pri čemu se kod navedenog inhibitora povratne apsorpcije serotonina radi o najmanje jednom lijeku odabranom iz skupine koju čine fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram i njihove soli, a kod navedenog inhibitora povratne apsorpcije serotonina i noradrenalina, radi se o najmanje jednom lijeku odabranom iz skupine koju čine venlafaksin, duloksetin, milnacipran, desvenlafaksin i njihove soli.
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound bixafen. 
("S N>N CH naznačen time da je R; difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj fludioksonil.
wherein the opening of each pair of vertical posts has a constant width; and 
umetanje para susjednih jedara (106a, 106b) kroz otvor (420) svakog para okomitih nosača (404, 406);
The compound of para 1, which is selected from: 
Spoj prema patentnom zahtjevu 1, koje je izabran od:
optionally followed by formation of the aldehyde of Formula 3: 
2 opcijski nakon toga slijedi stvaranje aldehida od Formule 3:
administering, in a therapeutically effective dose, a composition according to any one of claims 1 to 43 to the plant or to soil in proximity to the plant. 
davanje, u terapijski djelotvornoj dozi, sastava u skladu s bilo kojim od zahtjeva od 1 do 10 toj biljci ili u tlo u blizini biljke.
One-year outcomes will be reported at a later date. 
izgubljeno u kasnijoj fazi liječenja (n=f)
A molecule according to the use of claim 4, for use in the treatment or prevention of Alzheimer's disease, wherein said Alzheimer's disease is pre-clinical Alzheimer's disease. 
Molekula u skladu s patentnim zahtjevom 4, naznačena time što je namijenjena upotrebi u liječenju ili sprječavanju Alzheimerove bolesti, gdje je navedena Alzheimerova bolest pretklinički stadij Alzheimerove bolesti.
The method of claim 14, wherein the agent for treatment of hypertension is selected from the group consisting of an angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, a diuretic, a beta-blocker, and a calcium channel blocker. 
dok sredstvo za liječenje hipertenzije je inhibitor enzima pretvaranja angiotenzina, blokator receptora angiotenzina II, diuretik, beta blokator ili blokator kanala kalcija; ili
A plant according to claim 5 which is produced by a method according to claim 3. 
Biljka prema zahtjevu 5, naznačena time, da se ona proizvodi putem postupka prema zahtjevu 3.
In another embodiment of the invention there is provided a therapeutic antibody, which antibody comprises a heavy chain having the sequence set forth in SEQ ID No:34, 36 or 38 and a light chain having the sequence set forth in SEQ ID No:40. 
Terapijsko protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što sadrži teški lanac sa slijedom iznijetim u SEQ ID No0:34, 36 ili 38 i laki lanac sa slijedom iznijetim u SEQ ID No:40.
Method for searching for multimedia content items on the internet 
METODA PRETRAŽIVANJA MULTIMEDIJALNOG SADRŽAJA NA INTERNETU HR P20130186 T1
applying a solution comprising poly (ethylene glycol) having a concentration of about 10% by weight and glycine having a concentration of about 4% to 8% by weight to the cation exchange chromatography material, thereby separating the antibody of the IgG class in monomeric form with reduced host cell protein content from the antibody in aggregate form and obtaining the antibody in monomeric form with reduced host cell protein content. 
- proizvodnja protutijela IgG-razreda u monomernom obliku primjenom otopine koja sadrži poli(etilenglikol) i sorbitol na kromatografski materijal, te time desorbiranje / eluiranje protutijela IeG- razreda u monomernom obliku iz kromatografskog materijala, pri čemu poli(etilenglikol) ima koncentraciju od 10 masenih % 1 sorbitol ima koncentraciju od 5 masenih % do 20 masenih %.
each Rc4 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rd4 and/or Re4, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl; 
svaki Rc4 međusobno neovisno označava vodik ili skupinu, opcionalno supstituiranu s jednom ili više, istih ili različitih Rd4 i/ili Re4, odabranih između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-10-člani heteroaril i 310-člani heterociklil;
n is 2. A compound selected from: 
Spoj prema patentnom zahtjevu 1, izabran iz: